Los Angeles Capital Management LLC Takes $288,000 Position in Lifevantage Corporation $LFVN

Los Angeles Capital Management LLC bought a new stake in shares of Lifevantage Corporation (NASDAQ:LFVNFree Report) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 22,035 shares of the company’s stock, valued at approximately $288,000.

Other hedge funds have also added to or reduced their stakes in the company. Capital Management Corp VA lifted its stake in Lifevantage by 77.0% in the second quarter. Capital Management Corp VA now owns 1,266,110 shares of the company’s stock valued at $16,561,000 after buying an additional 550,607 shares during the period. Driehaus Capital Management LLC acquired a new position in shares of Lifevantage during the 1st quarter valued at $6,701,000. Russell Investments Group Ltd. boosted its stake in Lifevantage by 393,513.8% during the first quarter. Russell Investments Group Ltd. now owns 114,148 shares of the company’s stock worth $1,664,000 after acquiring an additional 114,119 shares in the last quarter. Trexquant Investment LP acquired a new stake in Lifevantage in the first quarter worth $1,607,000. Finally, Acadian Asset Management LLC grew its holdings in Lifevantage by 47.3% in the first quarter. Acadian Asset Management LLC now owns 291,700 shares of the company’s stock worth $4,248,000 after purchasing an additional 93,661 shares during the period. 35.32% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Michael A. Beindorff sold 35,000 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $6.92, for a total transaction of $242,200.00. Following the completion of the transaction, the director directly owned 56,413 shares of the company’s stock, valued at $390,377.96. This represents a 38.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 40,325 shares of company stock valued at $298,990 in the last 90 days. 21.95% of the stock is owned by insiders.

Lifevantage Trading Up 2.3%

Shares of Lifevantage stock opened at $6.62 on Monday. The stock has a fifty day simple moving average of $9.12 and a 200 day simple moving average of $11.54. The company has a market capitalization of $84.08 million, a P/E ratio of 8.95 and a beta of 0.22. Lifevantage Corporation has a 12-month low of $6.38 and a 12-month high of $27.38.

Lifevantage (NASDAQ:LFVNGet Free Report) last posted its earnings results on Tuesday, November 4th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.17 by $0.01. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. The firm had revenue of $47.56 million for the quarter, compared to analysts’ expectations of $54.74 million. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Lifevantage Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Monday, December 1st will be given a $0.045 dividend. The ex-dividend date of this dividend is Monday, December 1st. This represents a $0.18 annualized dividend and a yield of 2.7%. Lifevantage’s payout ratio is currently 23.38%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LFVN shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Lifevantage in a research report on Wednesday, October 8th. Lake Street Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Lifevantage in a research report on Wednesday, November 5th. Finally, Wall Street Zen downgraded shares of Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.50.

View Our Latest Stock Report on Lifevantage

Lifevantage Company Profile

(Free Report)

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Featured Stories

Want to see what other hedge funds are holding LFVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lifevantage Corporation (NASDAQ:LFVNFree Report).

Institutional Ownership by Quarter for Lifevantage (NASDAQ:LFVN)

Receive News & Ratings for Lifevantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifevantage and related companies with MarketBeat.com's FREE daily email newsletter.